The American Journal of Medicine
Volume 120, Issue 2 , Pages 109-120 , February 2007

Management of Post-Myocardial Infarction Patients with Left Ventricular Systolic Dysfunction

  • Mihai Gheorghiade, MD

      Affiliations

    • Division of Cardiology, Northwestern Feinberg School of Medicine, Chicago, Ill
    • Corresponding Author InformationRequests for reprints should be addressed to Mihai Gheorghiade, MD, Division of Cardiology, Northwestern Feinberg School of Medicine, 201 East Huron Street, Galter 10-240, Chicago, IL 60611.
    • ,
  • Gregg C. Fonarow, MD

      Affiliations

    • Ahmanson-UCLA Cardiomyopathy Center, The David Geffen School of Medicine at UCLA, Los Angeles, Calif.

References 

  1. American Heart Association. Heart Disease and Stroke Statistics—2005 Update. Dallas, TX: American Heart Association; 2005;
  2. Steg PG, Dabbous OH, Feldman LJ, et al. Determinants and prognostic impact of heart failure complicating acute coronary syndromes: observations from the Global Registry of Acute Coronary Events (GRACE). Circulation. 2004;109:494–499
  3. Amiodarone Trials Meta- Analysis Investigators. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials (Amiodarone Trials Meta- Analysis Investigators). Lancet. 1997;350:1417–1424
  4. Kober L, Torp-Pedersen C, Carlsen JE, et al. Trandolapril Cardiac Evaluation (TRACE) Study Group A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 1995;333:1670–1676
  5. Kober L, Torp-Pedersen C, Jorgensen S, et al. TRACE Study Group Changes in absolute and relative importance in the prognostic value of left ventricular systolic function and congestive heart failure after acute myocardial infarction (Trandolapril Cardiac Evaluation). Am J Cardiol. 1998;81:1292–1297
  6. Klein L, Gheorghiade M. Coronary artery disease and prevention of heart failure. Med Clin North Am. 2004;88:1209–1235
  7. Fonarow GC, Abraham WT, Cannon CP, et al. Role of beta-blocker therapy in the post-myocardial infarction patient with and without left ventricular dysfunction. Rev Cardiovasc Med. 2003;4(Suppl 3):S54–S59
  8. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction—executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation. 2004;110:588–636
  9. Hasdai D, Topol EJ, Kilaru R, et al. Frequency, patient characteristics, and outcomes of mild-to-moderate heart failure complicating ST-segment elevation acute myocardial infarction: lessons from 4 international fibrinolytic therapy trials. Am Heart J. 2003;145:73–79
  10. Velazquez EJ, Francis GS, Armstrong PW, et al. An international perspective on heart failure and left ventricular systolic dysfunction complicating myocardial infarction: the VALIANT registry. Eur Heart J. 2004;25:1911–1919
  11. Solomon SD, Zelenkofske S, McMurray JJ, et al. Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med. 2005;352:2581–2588
  12. Bolognese L, Neskovic AN, Parodi G, et al. Left ventricular remodeling after primary coronary angioplasty: patterns of left ventricular dilation and long-term prognostic implications. Circulation. 2002;106:2351–2357
  13. Gheorghiade M, Bonow RO. Chronic heart failure in the United States: a manifestation of coronary artery disease. Circulation. 1998;97:282–289
  14. Yusuf S, Peto R, Lewis J, et al. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985;27:335–371
  15. ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100000 patients in randomized trials (ACE Inhibitor Myocardial Infarction Collaborative Group). Circulation. 1998;97:2202–2212
  16. Ryan TJ, Antman EM, Brooks NH, et al. 1999 update: ACC/AHA Guidelines for the Management of Patients with Acute Myocardial Infarction: Executive Summary and Recommendations: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Circulation. 1999;100:1016–1030
  17. Pfeffer MA, Braunwald E, Moye LA, et al. The SAVE Investigators Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction (Results of the survival and ventricular enlargement trial). N Engl J Med. 1992;327:669–677
  18. AIRE Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure (The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators). Lancet. 1993;342:821–828
  19. Torp-Pedersen C, Kober L TRACE Study Group. Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction (Trandolapril Cardiac Evaluation). Lancet. 1999;354:9–12
  20. Ambrosioni E, Borghi C, Magnani B The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med. 1995;332:80–85
  21. Borghi C, Ambrosioni E. Double-blind comparison between zofenopril and lisinopril in patients with acute myocardial infarction: results of the Survival of Myocardial Infarction Long-term Evaluation-2 (SMILE-2) study. Am Heart J. 2003;145:80–87
  22. Yusuf S, Sleight P, Pogue J, et al. The Heart Outcomes Prevention Evaluation Study Investigators Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. [published errata appear in N Engl J Med 2000 Mar 9;342:748 and 2000 May 4;342:1376] N Engl J Med. 2000;342:145–153
  23. Fox KA, Poole-Wilson PA, Henderson RA, et al. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial (Randomized Intervention Trial of unstable Angina). Lancet. 2002;360:743–751
  24. Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial (Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan). Lancet. 2002;360:752–760
  25. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:1893–1906
  26. CAPRICORN Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357:1385–1390
  27. Freemantle N, Cleland J, Young P, et al. Beta-blockade after myocardial infarction: systematic review and meta-regression analysis. BMJ. 1999;318:1730–1737
  28. McMurray J, Kober L, Robertson M, et al. Antiarrhythmic effect of carvedilol after acute myocardial infarction (Results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial). J Am Coll Cardiol. 2005;45:525–530
  29. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309–1321
  30. Pitt B, White H, Nicolau J, et al. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol. 2005;46:425–431
  31. Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy—I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients (Antiplatelet Trialists’ Collaboration). BMJ. 1994;308:81–106
  32. Teo KK, Yusuf S, Pfeffer M, et al. Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review. Lancet. 2002;360:1037–1043
  33. Stenestrand U, Wallentin L. Early statin treatment following acute myocardial infarction and 1-year survival. JAMA. 2001;285:430–436
  34. Sacks FM, Pfeffer MA, Moye LA, et al. Cholesterol and Recurrent Events Trial investigators The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001–1009
  35. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22
  36. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495–1504
  37. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–1389
  38. Kjekshus J, Pedersen TR, Olsson AG, et al. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail. 1997;3:249–254
  39. Julian DG, Camm AJ, Frangin G, et al. European Myocardial Infarct Amiodarone Trial Investigators Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet. 1997;349:667–674
  40. Buxton AE, Lee KL, Fisher JD, et al. Multicenter Unsustained Tachycardia Trial Investigators A randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med. 1999;341:1882–1890
  41. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877–883
  42. Hohnloser SH, Kuck KH, Dorian P, et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med. 2004;351:2481–2488
  43. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58050 patients with suspected acute myocardial infarction. Lancet. 1995;345:669–685
  44. GISSI-3 InvestigatorsGruppo Italiano per lo Studio della Sopravvivenza nell’infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet. 1994;343:1115–1122
  45. Cleland JG, Erhardt L, Murray G, et al. Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure (A report from the AIRE Study Investigators). Eur Heart J. 1997;18:41–51
  46. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285:1711–1718
  47. de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA. 2004;292:1307–1316
  48. Hjalmarson A, Elmfeldt D, Herlitz J, et al. Effect on mortality of metoprolol in acute myocardial infarction (A double-blind randomised trial). Lancet. 1981;2:823–827
  49. Hjalmarson A, Herlitz J, Holmberg S, et al. The Goteborg metoprolol trial (Effects on mortality and morbidity in acute myocardial infarction). Circulation. 1983;67:I26–I32
  50. Herlitz J, Elmfeldt D, Holmberg S, et al. Goteborg Metoprolol Trial: mortality and causes of death. Am J Cardiol. 1984;53:9D–14D
  51. The MIAMI Trial Research Group. Metoprolol in acute myocardial infarction (Mortality). Am J Cardiol. 1985;56:15G–22G
  52. First International Study of Infarct Survival Collaborative Group. Randomised trial of intravenous atenolol among 16027 cases of suspected acute myocardial infarction: ISIS-1. Lancet. 1986;2:57–66
  53. Roberts R, Rogers WJ, Mueller HS, et al. Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction (Results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study). Circulation. 1991;83:422–437
  54. Lopressor Intervention Trial Research Group. The Lopressor Intervention Trial: multicentre study of metoprolol in survivors of acute myocardial infarction. Eur Heart J. 1987;8:1056–1064
  55. Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med. 1981;304:801–807
  56. Beta-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction (I. Mortality results). JAMA. 1982;247:1707–1714
  57. Beta-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction (II. Morbidity results). JAMA. 1983;250:2814–2819
  58. COREG (carvedilol) Tablets [prescribing information pamphlet] (CO:L9). Research Triangle Park, NC: GlaxoSmithKline; 2005;
  59. Tavazzi L, Tognoni G, Franzosi MG, et al. GISSI investigators Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. Eur J Heart Fail. 2004;6:635–641
  60. Kjekshus J, Dunselman PH, Blideskog M, et al. CORONA study Group A statin in the treatment of heart failure? (Controlled rosuvastatin multinational study in the heart failure (CORONA): study design and baseline characteristics). Eur J Heart Fail. 2005;7:1059–1069

PII: S0002-9343(05)00716-3

doi: 10.1016/j.amjmed.2005.08.010

The American Journal of Medicine
Volume 120, Issue 2 , Pages 109-120 , February 2007

Article Tools

* Image Usage & Resolution